In this study, we couple in vitro and in vivo models of UTI to examine the role of HIF-1α in host defense of the urinary tract against UPEC, with an eye toward pharmacological HIF-1α boosting as a novel therapeutic approach in this highly prevalent and difficult to manage infectious disease condition. This evidence concerns the gene HIF1A and infectious disease.